Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.

OBJECTIVE To determine the safety and efficacy of subretinal gene therapy in the RPE65 form of Leber congenital amaurosis using recombinant adeno-associated virus 2 (rAAV2) carrying the RPE65 gene. DESIGN Open-label, dose-escalation phase I study of 15 patients (range, 11-30 years of age) evaluated after subretinal injection of the rAAV2- RPE65 vector into the worse-functioning eye. Five cohorts represented 4 dose levels and 2 different injection strategies. MAIN OUTCOME MEASURES Primary outcomes were systemic and ocular safety. Secondary outcomes assayed visual function with dark-adapted full-field sensitivity testing and visual acuity with Early Treatment Diabetic Retinopathy Study charts. Further assays included immune responses to the vector, static visual fields, pupillometry, mobility performance, and optical coherence tomography. RESULTS No systemic toxicity was detected; ocular adverse events were related to surgery. Visual function improved in all patients to different degrees; improvements were localized to treated areas. Cone and rod sensitivities increased significantly in the study eyes but not in the control eyes. Minor acuity improvements were recorded in many study and control eyes. Major acuity improvements occurred in study eyes with the lowest entry acuities and parafoveal fixation loci treated with subretinal injections. Other patients with better foveal structure lost retinal thickness and acuity after subfoveal injections. CONCLUSIONS Gene therapy for Leber congenital amaurosis caused by RPE65 mutations is sufficiently safe and substantially efficacious in the extrafoveal retina. There is no benefit and some risk in treating the fovea. No evidence of age-dependent effects was found. Our results point to specific treatment strategies for subsequent phases. APPLICATION TO CLINICAL PRACTICE Gene therapy for inherited retinal disease has the potential to become a future part of clinical practice. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00481546.

[1]  A. Liem,et al.  PERSISTENT SUBFOVEAL FLUID AND INCREASED PREOPERATIVE FOVEAL THICKNESS IMPAIR VISUAL OUTCOME AFTER MACULA-OFF RETINAL DETACHMENT REPAIR , 2011, Retina.

[2]  L. Wheless,et al.  Regeneration of Photopigment Is Enhanced in Mouse Cone Photoreceptors Expressing RPE65 Protein , 2011, The Journal of Neuroscience.

[3]  David R Williams,et al.  Intravitreal injection of AAV2 transduces macaque inner retina. , 2011, Investigative ophthalmology & visual science.

[4]  John T. Thompson.  Advantages and limitations of small gauge vitrectomy. , 2011, Survey of ophthalmology.

[5]  Vladimir J. Kefalov,et al.  The Cone-specific visual cycle , 2011, Progress in Retinal and Eye Research.

[6]  A. V. Cideciyan,et al.  Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel. , 2010, Human gene therapy.

[7]  A. Cideciyan,et al.  Treatment possibilities for retinitis pigmentosa. , 2010, The New England journal of medicine.

[8]  A. J. Roman,et al.  Retinal disease in Rpe65-deficient mice: comparison to human leber congenital amaurosis due to RPE65 mutations. , 2010, Investigative ophthalmology & visual science.

[9]  Artur V. Cideciyan,et al.  Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy , 2010, Progress in Retinal and Eye Research.

[10]  G. Rubin,et al.  Visually-Guided Mobility in Patients Treated With Gene Therapy for Leber's Congenital Amaurosis , 2010 .

[11]  Jean Bennett,et al.  Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  Kathleen A. Marshall,et al.  Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial , 2009, The Lancet.

[13]  Alexander Sumaroka,et al.  Vision 1 year after gene therapy for Leber's congenital amaurosis. , 2009, The New England journal of medicine.

[14]  A. J. Roman,et al.  Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. , 2009, Human gene therapy.

[15]  Edwin M Stone,et al.  Defining the residual vision in leber congenital amaurosis caused by RPE65 mutations. , 2009, Investigative ophthalmology & visual science.

[16]  W. Hauswirth,et al.  Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. , 2008, Human gene therapy.

[17]  T. Aleman,et al.  Photoreceptor layer topography in children with leber congenital amaurosis caused by RPE65 mutations. , 2008, Investigative ophthalmology & visual science.

[18]  Edwin M Stone,et al.  Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics , 2008, Proceedings of the National Academy of Sciences.

[19]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[20]  Nick Tyler,et al.  Effect of gene therapy on visual function in Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[21]  Joan W. Miller.  Preliminary results of gene therapy for retinal degeneration. , 2008, The New England journal of medicine.

[22]  G. Rubin,et al.  Clinical Trial of Gene Therapy for Early Onset Severe Retinal Dystrophy Caused by Defects in RPE65 , 2008 .

[23]  A. J. Roman,et al.  Human cone photoreceptor dependence on RPE65 isomerase , 2007, Proceedings of the National Academy of Sciences.

[24]  A. J. Roman,et al.  Electroretinographic analyses of Rpe65-mutant rd12 mice: developing an in vivo bioassay for human gene therapy trials of Leber congenital amaurosis. , 2007, Molecular vision.

[25]  A. J. Roman,et al.  Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials , 2007, Physiological measurement.

[26]  Marc Korczykowski,et al.  Canine and Human Visual Cortex Intact and Responsive Despite Early Retinal Blindness from RPE65 Mutation , 2007, PLoS medicine.

[27]  K. Palczewski,et al.  Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agents. , 2007, Annual review of pharmacology and toxicology.

[28]  A. Wenzel,et al.  Lentiviral Gene Transfer of Rpe65 Rescues Survival and Function of Cones in a Mouse Model of Leber Congenital Amaurosis , 2006, PLoS medicine.

[29]  A. J. Roman,et al.  Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. , 2006, Human gene therapy.

[30]  Jan E Lovie-Kitchin,et al.  Measuring mobility performance: experience gained in designing a mobility course , 2006, Clinical & experimental optometry.

[31]  A. J. Roman,et al.  Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  Weng Tao,et al.  Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[33]  W. Hauswirth,et al.  Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  Ying Chen,et al.  RPE65 gene delivery restores isomerohydrolase activity and prevents early cone loss in Rpe65-/- mice. , 2006, Investigative ophthalmology & visual science.

[35]  W. Hauswirth,et al.  Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  M. Sandberg,et al.  The association between visual acuity and central retinal thickness in retinitis pigmentosa. , 2005, Investigative ophthalmology & visual science.

[37]  Geoffrey P. Lewis,et al.  Cellular remodeling in mammalian retina: results from studies of experimental retinal detachment , 2005, Progress in Retinal and Eye Research.

[38]  T. Aleman,et al.  Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  W. Hauswirth,et al.  Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA). , 2005, Molecular vision.

[40]  A. J. Roman,et al.  Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures. , 2005, Experimental eye research.

[41]  J. J. Neve,et al.  Improved mobility and independence of night-blind people using night-vision goggles. , 2004, Investigative ophthalmology & visual science.

[42]  B. Munoz,et al.  Association of Visual Field Loss and Mobility Performance in Older Adults: Salisbury Eye Evaluation Study , 2004, Optometry and vision science : official publication of the American Academy of Optometry.

[43]  P. Rakoczy,et al.  Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65-/- knockout mouse eye results in limited rescue , 2004, Genetic vaccines and therapy.

[44]  Krzysztof Palczewski,et al.  Impairment of the transient pupillary light reflex in Rpe65(-/-) mice and humans with leber congenital amaurosis. , 2004, Investigative ophthalmology & visual science.

[45]  T. Aleman,et al.  In utero gene therapy rescues vision in a murine model of congenital blindness. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  Jian-xing Ma,et al.  Identification of the RPE65 protein in mammalian cone photoreceptors. , 2002, Investigative ophthalmology & visual science.

[47]  Jean Bennett,et al.  Gene therapy restores vision in a canine model of childhood blindness , 2001, Nature Genetics.

[48]  K. Turano,et al.  Traditional Measures of Mobility Performance and Retinitis Pigmentosa , 1998, Optometry and vision science : official publication of the American Academy of Optometry.

[49]  S. Haymes,et al.  Comparison of Functional Mobility Performance with Clinical Vision Measures in Simulated Retinitis Pigmentosa , 1994, Optometry and vision science : official publication of the American Academy of Optometry.

[50]  S. Jacobson,et al.  Automated light- and dark-adapted perimetry for evaluating retinitis pigmentosa. , 1986, Ophthalmology.

[51]  R. Nussenblatt,et al.  Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. , 1985, Ophthalmology.

[52]  F. Ferris,et al.  New visual acuity charts for clinical research. , 1982, American journal of ophthalmology.

[53]  D. Anderson,et al.  The relationship of primate foveal cones to the pigment epithelium. , 1979, Journal of ultrastructure research.

[54]  M. Hogan,et al.  Signs and symptoms of uveitis. I. Anterior uveitis. , 1959, American journal of ophthalmology.

[55]  G. Holland,et al.  Laser flare-cell photometry: methodology and clinical applications. , 2005, Survey of ophthalmology.